Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial.

Ketty PerisTimothy J InocencioAlexander J StratigosKarl D LewisZeynep ErogluAnne Lynn S ChangCristina IvanescuAleksandar SekulicMatthew G FuryChieh-I ChenRuben G W Quek

Published in: Cancer medicine (2024)

The majority of patients treated with cemiplimab reported improvement or maintenance in GHS/QoL and functioning while maintaining a low symptom burden.

Keyphrases

basal cell carcinoma
risk factors
patient reported